Dr. Sudhindra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1000 10th Ave
New York, NY 10019Phone+1 212-636-3120
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2012 - 2015
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2009 - 2012
George Washington University School of Medicine and Health SciencesClass of 2009
Certifications & Licensure
CA State Medical License 2012 - 2021
NY State Medical License 2015 - 2017
FL State Medical License Active through 2013
Clinical Trials
- Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab Start of enrollment: 2017 Dec 29
- Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy Start of enrollment: 2017 Dec 29
- Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) Start of enrollment: 2019 Feb 19
Publications & Presentations
PubMed
- 28 citationsFLT3 Inhibitors in AML: Are We There Yet?Akshay Sudhindra, Catherine C. Smith
Current Hematologic Malignancy Reports. 2014-03-30 - 23 citationsBiomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment.Akshay Sudhindra, Roberto Ochoa, Edgardo S. Santos
Clinical Lung Cancer. 2011-11-01 - 6 citationsCarfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.Swetha Kambhampati, Bita Fakhri, Weiyun Z. Ai, Lawrence D. Kaplan, Joseph Tuscano
Clinical Lymphoma, Myeloma & Leukemia. 2021-03-01
Press Mentions
Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual MeetingDecember 3rd, 2018- Don't Miss Out!November 1st, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
